Legal & General Group
OBIO icon

Legal & General Group’s Orchestra BioMed OBIO Stock Holding History

Legal & General Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,225
Closed -$9.52K – 3499
2025
Q1 		$9.52K Hold
2,225
– – ﹤0.01% 3181
2024
Q4 		$8.89K Hold
2,225
– – ﹤0.01% 3273
2024
Q3 		$11.4K Hold
2,225
– – ﹤0.01% 3246
2024
Q2 		$18.1K Buy
2,225
+717
+48% +$4.15K ﹤0.01% 3061
2024
Q1 		$7.95K Hold
1,508
– – ﹤0.01% 3250
2023
Q4 		$13.8K Hold
1,508
– – ﹤0.01% 3168
2023
Q3 		$13.2K Sell
1,508
-7,630
-83% -$51.3K ﹤0.01% 3202
2023
Q2 		$63.9K Buy
+9,138
New +$139K ﹤0.01% 2854

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's OBIO Position: Q2 2025 in Review

Legal & General Group sold out of Orchestra BioMed (OBIO) in Q2 2025, closing a stake of 2,225 shares — an estimated $9.52K sold.

Legal & General Group first reported a position in OBIO in Q2 2023 and held it in 8 quarters. The position peaked at $63.9K in Q2 2023. 59 funds tracked by Wall St. Rank hold OBIO as of Q2 2025.

  • Legal & General Group reported no remaining Orchestra BioMed position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 2,225 Orchestra BioMed shares in Q2 2025, an estimated $9.52K.
  • Legal & General Group first reported a position in Orchestra BioMed in Q2 2023 and held it in 8 quarters.
  • Legal & General Group's Orchestra BioMed position peaked at $63.9K in Q2 2023.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.